Robitussin DM: Clinical Information
Robitussin DM (dextromethorphan/guaifenesin combination) is indicated for symptomatic relief of cough and chest congestion associated with upper respiratory infections, though evidence shows guaifenesin lacks efficacy for cough suppression while dextromethorphan provides modest cough reduction in adults.
Indications
Robitussin DM combines two active ingredients:
- Dextromethorphan (DM): Cough suppressant that modestly decreases cough frequency and severity in adults 1
- Guaifenesin: Marketed as an expectorant to loosen mucus, though ACCP guidelines explicitly state that agents altering mucus characteristics are NOT recommended for cough suppression in chronic bronchitis 2
The combination is FDA-approved for loosening and relieving chest congestion 3, though the evidence supporting guaifenesin's efficacy is limited. Studies show dextromethorphan provides statistically significant reductions in cough frequency/severity compared to placebo, while guaifenesin data are conflicting 1.
Dosing Guidelines
Per FDA labeling 3:
Adults and children ≥12 years:
- 2-4 teaspoonfuls every 4 hours
- Do not exceed recommended dosage
Children 6 to <12 years:
- 1-2 teaspoonfuls every 4 hours
Children <6 years:
- Do not use
Extended-release formulations allow 12-hourly dosing for convenience 4.
Contraindications and Safety Precautions
Critical Drug Interactions
- Absolute contraindication with MAOIs: Coadministration of dextromethorphan with monoamine oxidase inhibitors poses significant safety concerns 5
- Exercise caution in patients taking cyclosporine if using combination products containing diphenhydramine 6
Special Populations
- Liver impairment/transplant: Use dextromethorphan with greater caution 6
- Renal impairment/kidney transplant: Use guaifenesin with caution; monitor carefully 6
- Lung transplant recipients: Exercise caution with guaifenesin 6
Adverse Effects
Dextromethorphan adverse reactions are infrequent and usually not severe, but include 5:
- Neurological disturbances (dose-related)
- Cardiovascular effects
- Gastrointestinal symptoms
- Abuse potential is the most significant hazard identified 5
Rare but Serious Complications
One case report documented bilateral nephrolithiasis and acute renal failure following guaifenesin/dextromethorphan misuse, suggesting prolonged nephrolith formation with combination ingestion 7.
Clinical Efficacy Considerations
Key evidence limitations:
- Antihistamines, antihistamine-decongestant combinations, and guaifenesin do NOT provide greater relief than placebo in adults 8
- In children, dextromethorphan does not relieve cough better than placebo (honey is superior) 8
- ACCP guidelines give guaifenesin a Grade D recommendation (no benefit) for cough suppression 2
The modest benefit comes primarily from dextromethorphan, not guaifenesin. Clinical efficacy is most established in chronic respiratory conditions where symptoms are stable, rather than acute URIs 4.
Common Pitfalls
- Do not expect significant expectorant effects from guaifenesin despite marketing claims
- Avoid use in children under 6 years per FDA labeling
- Screen for MAOI use before recommending
- Be aware of abuse potential, particularly in young adults
- Do not use as monotherapy for chronic bronchitis—ipratropium bromide is the only recommended inhaled agent for this indication 2